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Abbreviations:  
ACP = acute cor pulmonale; ARDS = acute respiratory distress syndrome; ASE = 
American Society of Echocardiography; CI = confidence interval;  CMV = conventional 
mechanical ventilation; CO2 = carbon dioxide; CRRT = continuous renal replacement 
therapy; CT = computed tomography; CRRT = continuous renal replacement therapy; 
CVP = central venous pressure; DTI = doppler tissue imaging; E/E' = the ratio of early 
tricuspid inflow to annular diastolic velocity; EF = ejection fraction; ET-1 = endothelin 1; 
ECCO2R = extracorporeal CO2 removal; FAC = fractional area change; FiO2 = fraction of 
inspired oxygen;  5HT = 5-hydroxytryptamine; HFOV = high frequency oscillatory 
ventilation;  ICU = intensive care unit; LPV = lung protective ventilation; LVEDA = left 
ventricular end-diastolic area; MAP = mean arterial pressure; mPAOP =  mean 
pulmonary artery occlusion pressure; MPI = myocardial performance index; MRI = 
magnetic resonance imaging; PAC = pulmonary artery catheter; PaCO2 = partial pressure 
of arterial carbon dioxide; PaO2 = partial pressure of arterial oxygen; PAOP = pulmonary 
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artery occlusion pressure; sPAP = systolic pulmonary artery pressure; PBW = predicted 
body weight; PCWP = pulmonary capillary wedge pressure; PDE = phosphodiesterase; 
PEEP = positive end-expiratory pressure; PLR = passive leg raise; PPV = pulse pressure 
variation; PVR = pulmonary vascular resistance; PVRi = pulmonary vascular resistance 
index; RCT= randomized controlled trial; RIMP = right ventricular index of myocardial 
performance; RV = right ventricle; RVD = right ventricular dysfunction; RVEDA = right 
ventricular end-diastolic area; RVFAC = right ventricular fractional area change; RVEF 
= right ventricular ejection fraction; RVTDI = right ventricular tissue Doppler imaging; 
sPAP = systolic pulmonary arterial pressure;  SpO2 = oxygen saturation;  SVI = stroke 
volume index; TAPSE = tricuspid annular plane systolic excursion; TEE = 
transesophageal echocardiography; TPG = transpulmonary gradient; 3D = three 
dimensional; TTE = transthoracic echocardiography; VAECMO = veno-arterial 
extracorporeal membrane oxygenation; VVECMO = veno-venous extracorporeal 
membrane oxygenation; 
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ABSTRACT 
 
Acute respiratory distress syndrome is associated with poor clinical outcomes with a 
pooled mortality rate of approximately 40% despite best standards of care. Current 
therapeutic strategies are based upon improving oxygenation and pulmonary compliance 
while minimizing ventilator induced lung injury. It has been demonstrated that relative 
hypoxemia can be well tolerated and improvements in oxygenation do not necessarily 
translate into survival benefit. Cardiac failure, in particular right ventricular dysfunction, 
is commonly encountered in moderate to severe acute respiratory distress syndrome and 
is reported to be one of the major determinants of mortality. The prevalence rate of 
echocardiographically evident right ventricular dysfunction in acute respiratory distress 
syndrome varies across studies ranging from 22% to 50%. Although there is no definitive 
causal relationship between right ventricular dysfunction and mortality, severe right 
ventricular dysfunction is associated with increased mortality. Factors that can adversely 
affect right ventricular function include hypoxic pulmonary vasoconstriction, 
hypercapnia, and invasive ventilation with high driving pressure. It might be expected 
that early diagnosis of right ventricular dysfunction would be of benefit however, 
echocardiography markers (qualitative and quantitative) used to prospectively evaluate 
the right ventricle in acute respiratory distress syndrome have not been tested in 
adequately powered studies. In this review we examine the prognostic implications and 
pathophysiology of right ventricular dysfunction in acute respiratory distress syndrome 
and discuss available diagnostic modalities and treatment options. We aim to identify 
gaps in knowledge and directions for future research that could potentially improve 
clinical outcomes in this patient population. 
 
 
KEY WORDS: acute respiratory distress syndrome, right ventricular dysfunction, cor-
pulmonale, critical care echocardiography 
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Acute respiratory distress syndrome (ARDS) is characterized by the acute development 
of hypoxemia and bilateral lung infiltrates. 1 Five decades after it was first described and 
despite lung protective mechanical ventilation strategies2, 3 and other therapeutic 
advances such as prone positioning, fluid restrictive therapy and neuromuscular 
blockade,4-6 ARDS is still associated with substantial morbidity and mortality. In a 
systematic review and meta-analysis that included 89 ARDS studies (53 observational, 36 
randomized controlled trials), Phua et al found that the overall pooled weighted mortality 
was 44.3% (95% confidence interval [CI], 41.8-46.9). 7 In a recent randomized controlled 
trial (RCT) comparing conservative (SpO2 88–92%) versus a liberal oxygenation target 
(≥96%), there were no significant differences in organ dysfunction or mortality between 
the two groups. These results suggest that patients can survive short periods of relative 
hypoxemia without significant adverse effect and that hypoxemia may not be the leading 
cause of mortality in ARDS. 8 On the other hand, hemodynamic instability in the context 
of ARDS appears to be strongly associated with mortality.9 One potential mechanism is 
the dysfunction of the right ventricle (RV) and pulmonary vasculature which is often 
underappreciated in ARDS.10 As a result the RV fails to deliver adequate cardiac output 
to the left sided circulation thus resulting in systemic hypoperfusion and multiple organ 
dysfunction. 11 
 
The aim of the current review is to discuss the epidemiology of RV dysfunction (RVD) in 
ARDS and its effect on clinical outcomes, examine the current state of knowledge in the 
pathophysiology of RV dysfunction, identify gaps and explore the use of novel imaging 
markers, preventive and therapeutic strategies. Unanswered questions such as 
effectiveness of ‘low lung-stress’ ventilation, timing of proning and whether RVD alone 
should be an indication for proning, the role of extracorporeal life support and natural 
history of RVD in ARDS survivors will be discussed. 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
DEFINITIONS 
 
There is a variety of definitions for RV dysfunction (RVD) and failure (RVF) in the 
literature with the terms being used interchangeably at times. According to the American 
Society of Echocardiography (ASE) RVD is present when the parameters to quantify RV 
function are less than the lower value of the normal range: tricuspid annular plane 
systolic excursion (TAPSE) < 17mm, pulsed Doppler S wave < 9.5cm/sec, RV fractional 
area change (RVFAC) < 35%, RV ejection fraction (RVEF) < 45%. RVFAC has been 
used to grade the degree of RVD as mild (25-35%), moderate (18-25%) and  severe 
(<18%).12, 13 RVF is defined as the inability of the RV to provide adequate blood flow 
through the pulmonary circulation at normal central venous pressure (CVP).11 Acute cor 
pulmonale (ACP) refers to acute dilatation and/or dysfunction of the RV in the context of 
acute lung disease (eg ARDS) and associated pulmonary vascular dysfunction.14 ACP is a 
form of RVD due to acute increase in RV afterload that may lead to RVF and it is defined 
echocardiographically as septal dyskinesia with a ratio of right ventricular end-diastolic 
area (RVEDA): left ventricular end-diastolic area (LVEDA) greater than 0.6 (greater than 
1 for severe dilatation). In the RV-focused view, RV diameter greater than 41mm at the 
base and greater than 35mm at midlevel indicates chamber dilatation.12, 13 In this review 
we have chosen to use the term ‘RVD’ instead of ‘ACP’ as it provides a broader 
overview of RV pathology in acute pulmonary disease. Assessment of the RV by 
echocardiography is discussed further in the ‘diagnosis’ section of this review. 
 
 
EPIDEMIOLOGY & PROGNOSIS 
 
The reported incidence of RVD in ARDS varies across studies (22% to 50% (Table 1).15-
24) Although there is no robust evidence to support a definitive causal relationship 
between RVD and mortality in ARDS, it has been shown that RVD has a negative impact 
on the ARDS course and that severe RVD is associated with increased mortality even 
during lung protective mechanical ventilation.  
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In a prospective multicentre study (n= 200), Lhéritier et al 19 showed that ARDS patients 
with RVD (assessed by transthoracic (TTE) or transesophageal echocardiography (TEE) 
and defined as ACP), received prone mechanical ventilation and vasoactive therapy  
more frequently, and required higher dose of inhaled nitric oxide (NO) as a rescue 
therapy, than those without RVD. The incidence of RVD in this study was 22.5% (95% 
CI 19.9-28.9%). In a prospective observational study 20 which enrolled 226 patients with 
moderate to severe ARDS (Berlin definition) 25 RVD was detected in 22% and was found 
to be an independent predictor of 28-day mortality (p<0.01). A secondary analysis 22 of 
the Fluid and Catheter Treatment Trial (FACTT) examined the association between 
pulmonary vascular dysfunction, (defined as elevated transpulmonary gradient (TPG) or 
increased pulmonary vascular resistance index (PVRi) assessed by pulmonary artery 
catheter (PAC)) and outcomes in ARDS patients. Increased baseline TPG was associated 
with higher 60-day mortality (30 vs 19%; p<0.02) and PVRi was statistically higher in 
non-survivors (326 [209–518] versus 299 [199–416]; p = 0.01). Of note, the median 
PVRi was highest [304.6 (204.3–430.9)] early in the course of ARDS (Day 0 and Day 1).   
 
Mekontso Desapp and colleagues 17 undertook a large prospective observational study 
(n=752) in which patients with moderate to severe ARDS receiving the least damaging 
mechanical ventilation (low tidal volume and plateau pressure < 30 mmHg) were 
assessed using TEE. 22% of the cohort (95% CI 19-25%) had RVD (defined as ACP) and 
7.2% of patients had severe RV dilatation (RVEDA/LVEDA>1). Hospital mortality did 
not differ between patients with or without RVD but was significantly higher in patients 
with severely dilated RV [31/54 (57 %) vs. 291/698 (42 %); p = 0.03] which was also 
found to be an independent predictor of mortality. This could be explained by the fact 
that this subset of patients had established RVF which was unresponsive to therapeutic 
interventions aimed at decreasing RV afterload and ‘protecting’ the RV.17 On the other 
hand, patients with mildly dilated RV and septal dyskinesia included in the RVD group 
may have had preserved RV systolic function and this might explain the insignificant 
difference in mortality between the patients with or without RVD as defined by the 
authors. Patients enrolled had only a single TEE study during the first three days of 
ARDS diagnosis and therefore the natural history of RVD in ARDS remains unknown.17  
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Those studies assessing RV function in ARDS have not examined the impact of temporal 
changes in RV function on mortality, the natural history of RV function in survivors, nor 
the reversibility of RVD with progression of ARDS (Table 1). Whether patients with 
ARDS develop RV diastolic dysfunction, that might affect clinically important outcomes, 
also remains unknown. In most studies, RVD is defined as RV dilatation with or without 
septal dyskinesia. The clinical significance of isolated RV dilatation as a ‘red flag’ and its 
impact on mortality remain unclear. Only two studies used an ASE criterion (TAPSE) to 
define RVD (Table 1). 15, 16 There is a need for a consensual definition that reflects the 
pathophysiology of RVD in the context of ARDS and positive pressure ventilation. This 
will enable intensive care specialists to identify patients at risk of RVF and implement 
strategies that may protect the RV. 
 
 
PATHOPHYSIOLOGY 
 
The RV is responsible for maintaining adequate pulmonary perfusion pressure in order to 
deliver desaturated mixed venous blood to the respiratory membrane and low systemic 
venous pressure to prevent organ congestion. The RV is sensitive to changes in afterload 
because it is anatomically adapted for the generation of low-pressure perfusion.11, 26 
 
Why is the RV failing in ARDS? 
 
RVD is not always associated with an increase in PVR and pulmonary arterial 
hypertension; it can also be secondary to primary contractile impairment.11 As a result, 
low cardiac output (CO) with low mean arterial pressure (MAP) can occur. This can  
develop into in a vicious cycle, leading to a progressive downward spiral and cardiogenic 
shock.11,  26 
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Mekontso Desapp et al,17 reported four parameters (one clinical and three physiological) 
that were identified as statistically significant predictors of RVD in ARDS: 1) lower 
respiratory tract infection as a cause of pulmonary ARDS, 2) partial pressure of arterial 
oxygen : fraction of inspired oxygen (PaO2:FiO2 ) ratio < 150 mmHg, 3) PaCO2 > 48 
mmHg and 4) driving pressure (plateau pressure – total positive end expiratory pressure) 
> 18 cmH2O. These variables had a statistically significant correlation with RVD. 
Patients with an RVD score greater than or equal to 2 had a higher incidence of RVD 
(19%, 34% and 74% for risk scores of 2, 3 and 4 respectively). The authors recommend 
that echocardiography should be routinely performed in all ARDS patients with a score > 
2. There is lack of data that illustrate sequential relation of any of the above four 
parameters and severity of RVD. Although the RVD risk score has not yet been 
validated, it may provide a framework whereby researchers could test the hypothesis that 
early echocardiography and early implementation of RV protective measures and 
modification of the above physiological parameters might prevent RV failure and reduce 
mortality in patients with ARDS. 17 
 
 
Pulmonary Vascular Tone 
 
Elevated pulmonary vascular tone in ARDS could be due to a variety of causes including 
an imbalance between vasoconstrictors and vasodialators, endothelial injury, arteriolar 
hypoxic pulmonary vasoconstriction, hypercapnia, acidemia, in situ thrombosis, and 
muscularization of non-muscularized arteries (pulmonary vascular remodeling).27-29 
Raised PVR may lead to acute distension of the thin-walled and ‘afterload-sensitive’ RV 
resulting in increased oxygen demand, decreased  right coronary artery perfusion-
pressure with reduced oxygen delivery, and tricuspid annular dilatation worsening 
tricuspid regurgitation and exacerbating volume overload.  In addition RV dilatation can 
cause shifting of the interventricular septum toward the left impeding left ventricular 
diastolic filling and reducing left ventricular stroke volume, potentially leading to 
systemic hypotension. This phenomenon is known as ‘ventricular interdependence’.26, 30 
It has been shown that pulmonary hypertension may cause RV diastolic dysfunction 
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which is related to impaired RV mechanical compliance and elevated RV afterload and 
does improve by reducing the afterload. RV diastolic dysfunction and diastolic 
ventricular interaction again has not been systematically studied in the context of 
ARDS.31 
 
 
The role of Carbon Dioxide (CO2)  
 
Contributors to acute hypercapnia in ARDS include physiological factors such as 
increased alveolar dead space causing ventilation-perfusion mismatch and clinical factors 
such as low tidal volume/high respiratory rate ventilatory strategy in order to reduce the 
risk of ventilator induced lung injury. The role of acute hypercapnic acidemia in the 
pathophysiology of ARDS is not fully understood. Despite its potentially beneficial anti-
inflammatory effect on pulmonary cytokines 32, 33 hypercapnia could also exacerbate 
hypoxic pulmonary vasoconstriction or induce direct vasoconstriction of the pulmonary 
vasculature by increasing extracellular Ca++ influx. 34, 35 Pulmonary vasoconstriction 
induces an increase in arterial elastance of the pulmonary vascular system (Ea), whereas 
the RV system is characterized by the RV elastance (Ees). The ratio Ees/Ea reflects the 
mechano-energetic aspects of RV-pulmonary vascular coupling which is of paramount 
importance for cardiovascular performance as it determines RV systolic pressure and RV 
stroke volume. When Ees/Ea is >1 the system is coupled providing adequate RV 
performance, stroke work and right coronary blood flow. Hypercapnia-induced increase 
in RV afterload results in increased Ea and RVD may develop due to uncoupling between 
the RV and pulmonary circulation.36, 37 Experimental studies have shown that the 
buffering of respiratory acidosis is associated with worsening of ARDS.38 This 
observation suggests that some of the beneficial anti-inflammatory effects of respiratory 
acidosis are likely to be due to the acidemia rather than hypercapnia alone.38 A secondary 
analysis of the ARDSnet trial data3 showed that hypercapnic acidemia in ARDS patients 
who were mechanically ventilated with high tidal volumes (12ml/kg predicted body 
weight) was associated with reduced 28-day mortality. However, the authors did not 
examine the effect of hypercapnic acidemia on outcomes at various time-points or over 
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time and due to its observational nature this study could not prove a cause-effect 
relationship between hypercapnic acidemia and mortality benefit. 39 
 
 
It has been demonstrated that patients with severe ARDS, and hypercapnic acidemia 
induced by low tidal volume ventilation and high positive-end expiratory pressure 
(PEEP) at a constant plateau pressure, are likely to develop RVD.40 Vieillard-Baron and 
colleagues found that the partial pressure of arterial carbon dioxide (PaCO2) is an 
independent predictor of RVD in patients with ARDS receiving protective ventilation 
(p<0.0001).24 In another study which included 200 patients with moderate to severe 
ARDS, PaCO2 > 60mmHg was strongly associated with RVD [odds ratio (OR) 3.70; 95 
% CI 1.32–10.38; p = 0.01]. 19 
 
 
Positive Pressure Ventilation 
 
Patients with ARDS typically have considerably reduced functional residual capacity 
(FRC) and overall lung compliance and a need for an elevated airway pressure to 
adequately maintain alveolar recruitment.  This approach may have deleterious 
hemodynamic consequences.41 Positive pressure mechanical ventilation causes an 
increase in transpulmonary pressure (difference between alveolar and pleural pressure) 
which worsens non-physiological lung ‘stress’ and strain (ratio between tidal volume and 
functional residual capacity).42 PEEP, tidal volume and lung compliance are the main 
determinants of lung stress caused by positive pressure invasive ventilation which 
highlights the need for optimal mechanical ventilation strategies. When transpulmonary 
pressure exceeds pulmonary venous pressure, it acts as a back-pressure for pulmonary 
venous return and may increase the RV afterload.43, 44 
 
Increased PVR occurs at the extremes of lung volume. At low volumes it is caused by the 
elastic recoil forces of the lung parenchyma causing extra-alveolar vessel and terminal 
airway collapse leading to alveolar hypoxia and hypoxic pulmonary vasoconstriction.  At 
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high lung volumes increased PVR may occur due to collapse of the alveolar vessels 
consequent to the tension of the alveolar wall. When PVR is graphically plotted against 
lung volume, a U-shaped relation is observed with the lowest PVR occurring at the FRC. 
45
 
 
In ARDS, the distribution of intrapulmonary gas is heterogeneous with collapsed alveoli 
coexisting with normally aerated lung areas.46 High PEEP levels can cause hyperinflation 
of the normally aerated alveoli and intra-alveolar vessel compression leading to high 
PVR and increased RV afterload.47 The effect of PEEP on the RV outflow impedance in 
the context of ARDS has been evaluated by pulmonary artery flow velocity using TEE. 
High PEEP (13+4cmH2O) was associated with a significant reduction in RV stroke index 
47 High plateau pressure (> 27 cmH2O) has been associated with a high incidence of RVD 
(up to 60%) and high mortality rates (up to 42%) in ARDS 48.  Driving pressure (as a 
surrogate of lung stress) has recently been found to be a ventilation variable that is 
strongly associated with survival and RVD risk.17, 49 
 
This suggests that it is the stress and strain on the lung that poses risks of abnormal RV 
physiology. Unfortunately, there is lack of prospective data on whether a ‘low pressure’ 
ventilatory approach is ‘RV-protective’. Also, it remains unknown as to how much the 
chest wall contributes to the calculated airway pressures and whether this needs to be 
taken into account when attempting to risk stratify patients for RVD in ARDS. 
 
Sepsis 
In sepsis-related ARDS (pulmonary or extra-pulmonary), RVD can be an early 
phenomenon and appears to be associated with increased circulating levels of endothelin-
1 (ET-1). 50 High ET-1 levels in sepsis are inversely correlated to RV function. A 
proposed mechanism for RVD in sepsis is increased PVR due to endothelial dysfunction 
and altered vaso-reactivity, despite systemic vasodilatation. (SVR). 26, 50, 51 
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DIAGNOSIS OF ACUTE RIGHT VENTRICULAR DYSFUNCTION 
 
1. Hemodynamic Monitoring 
Standard hemodynamic monitoring can provide direct and indirect evidence suggesting 
the development of acute RVD.  It is important to identify and diagnose patients with 
RVD early, so that interventions aimed at reducing the sequelae may be initiated.    
 
Arterial line monitoring can detect the development of pulse pressure variation (PPV) and 
allows real-time blood pressure monitoring. PPV refers to dynamic changes of arterial 
pulse pressure (systolic blood pressure – diastolic blood pressure) induced by mechanical 
ventilation which can be derived from the arterial pressure waveform analysis and is 
thought to predict fluid responsiveness. In the context of low tidal volumes and a low 
pulmonary compliance state such as ARDS, the presence of PPV may signify either 
volume responsiveness or elevated RV afterload.52-54 Of note, for the assessment of PPV 
to be valid the patient must not be spontaneously breathing, and must be receiving an 
appropriate controlled tidal volume and be in a regular heart rhythm.  If the patient is 
deemed to be potentially volume responsive, a volume challenge may be given that will 
both confirm hypovolemia and subsequently improve RV outflow.  If the PPV is due to 
elevated RV afterload (and not secondary to reduced RV preload), a fluid challenge will 
not reduce the PPV and may in fact worsen RV outflow. In such cases PPV cannot be 
used as a reliable predictor of fluid responsiveness. However, in patients with elevated 
PPV who are ‘fluid-unresponsive’ RVD due to elevated RV afterload should be 
suspected and investigated promptly with echocardiography.55  
 
CVP monitoring directly measures right atrial (RA) pressure and although it is considered 
a poor predictor of fluid responsiveness it could be useful when values are particularly 
low or high (patients with very low CVP are likely to be ‘fluid-responsive’ and those 
with very high CVP are likely to be ‘non-responders’). A rapid increase in CVP 
following a fluid challenge could serve as an indicator of impending RVD or RVF when 
fluid resuscitation exceeds the normal RV unstressed volume operation range.56, 57   
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2. Pulmonary Artery Catheter (PAC) 
The traditional method of diagnosing RVD was to use a PAC. Given the potential risks of 
placement and development of less invasive methods of investigating cardiac function, 
the use of a PAC is now much less common. 57 
 
If a PAC is placed, then the usual findings suggestive of RVD include an elevated CVP 
(greater than 20mmHg), a CVP greater than pulmonary artery occlusion pressure, and a 
low cardiac index (< 2.0 L/min/m2) and mixed-venous oxygen saturation (SvO2 < 55%).  
The pulmonary vascular resistance is usually elevated in ARDS. 22 In addition, a PAC 
can be used to estimate the trans-pulmonary gradient (mean PA pressure – pulmonary 
artery occlusion pressure) which is also a marker of pulmonary vascular dysfunction 
which better estimates the resistance of the pulmonary vasculature in ARDS where West 
zones 1 and 2 can be abnormally extended due to increased transpulmonary pressure.22     
 
The challenges of using the PAC include the risks of insertion and measurement of the 
wedge pressure.  Its advantages, once placed, are the ease and rapidity of performing 
repeated measurements, particularly if many interventions to the patient’s physiology are 
made. However, use of PAC in ARDS should probably be reserved for those patients 
with echocardiographic evidence of severe RVD at risk of RVF or patients with 
established RVF to guide inodilator and/or pulmonary vasodilator therapy and monitor 
the effect of ventilatory strategy on PVR.  
 
There is a lack of data demonstrating the links between the rate of change in PVR and its 
implications for the management and prognosis of patients with ARDS. A potentially 
novel approach for these patients would be the use of pulmonary vasodilators early in the 
course of ARDS and testing of the hypothesis that this strategy might improve clinical 
outcomes. 
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3. Echocardiography 
The availability of and experience with critical care echocardiography has increased 
exponentially over the past decade. Now echocardiography is generally readily available 
and accessible in the ICU. Lhe´ritier et al showed that TEE is superior to TTE for 
diagnosing RVD in mechanically ventilated patients with moderate to severe ARDS. The 
authors found that using TEE as a reference the sensitivity of TTE for diagnosing RVD in 
ARDS was only 60% (95% CI 41-77%).19 Main limitation of the TEE approach is that 
serial repeat studies are more labor intensive and potentially of risk. 19, 58, 59 RVD by 
echocardiography is commonly defined as the presence of features of pressure and/or 
volume overload of the right ventricle. 14 RV volume overload is defined as dilation of 
the RV.  RV pressure overload is defined as dyskinetic movement of the septum during 
end-systole. RV volume overload can lead to pressure overload and vice versa. 60   
 
There are several qualitative and quantitative methods of interrogating the RV using 
echocardiography. 
 
2D echocardiography provides a visual appearance of the RV.  Based on this, RV global 
systolic function can be estimated.  Measurement of the RV end-diastolic dimensions and 
volumes can be made, and comparison with the left ventricle can be performed.  The RV 
is considered dilated when the RVEDA:LVEDA ratio is greater than 0.6.61, 62  In addition, 
evidence of systolic and diastolic septal dyskinesia (suggestive of RV pressure overload) 
can be determined on parasternal short axis and apical four chamber views.  
 
Quantitative assessment of RV function can be performed by several methods.  TAPSE 
can be obtained routinely and correlates well with RV function 12, 15, 16, 58 Interpretation of 
the TAPSE has two potential pitfalls however, it assumes the single segment represents 
the function of the entire RV, and its measurement is angle dependent.63   
 
The role of echocardiographic markers of global RV systolic function (such as right 
ventricular index of myocardial performance (RIMP), Doppler tissue imaging (DTI) - 
derived S’wave velocity, RV strain and RV strain rate or three-dimensional (3D) 
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echocardiographic RV ejection fraction (EF) 12) as early predictors of RVD in ARDS has 
not been studied to date. The prognostic implications of measures of diastolic RVD in 
ARDS (such as the ratio of early tricuspid inflow to annular diastolic velocity (E/E')63) 
have not been investigated either. It is possible that a predictive model based on 
echocardiographic and clinical (Berlin ARDS criteria and Mekontso Desapp clinical risk 
score) data could be developed to facilitate clinical decision making in patients with 
ARDS.   
 
4. Advanced Cardiac Imaging and Biomarkers 
Currently there is limited role for advanced cardiac imaging such as cardiac computed 
tomography (CT) or magnetic resonance imaging (MRI).  MRI is hindered by its 
availability and also the need for low heart rates to enable appropriate gating and study 
acquisition (this is often technically difficult with critically ill patients). Attempts to 
demonstrate cardiac CT’s ability to predict RV failure have been largely unsuccessful to 
date.64, 65  
 
Limited data exists on the role of BNP in the prognostication of ARDS patients with 
RVD.  In contrast, a recent study looking at patients with moderate to severe ARDS 
demonstrated that an elevated troponin, in conjunction with echo findings of RVD, 
identified a high-risk subgroup with elevated mortality. 18 
 
 
TREATMENT 
 
The treatment of RV dysfunction can be divided into several physiological targets 
including optimization of RV preload, increasing RV contractility, and reducing RV 
afterload. Extracorporeal life support (veno-venous or veno-arterial extracorporeal 
membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R)) may be 
considered as rescue therapy in refractory cases of ARDS and RVF.  
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1. Optimization of RV preload 
Meticulous management of volume status is crucial for the failing RV, as both low and 
high filling pressures may result in reduced CO.  In patients where hypovolemia is 
suspected volume loading may increase CO.66 This must be done cautiously as elevated 
pulmonary pressures (mean PAP greater than 30 mmHg), as seen in ARDS, may prevent 
a resultant increase in RV contractility and CO.30 Excessive volume loading inhibits 
stroke volume by altering the geometry of the RV resulting in RV dilatation, ventricular 
interdependence, and impaired LV diastolic compliance. 67 RV dilatation may also cause 
increased tricuspid regurgitation and right sided venous congestion. A ‘mini-fluid 
challenge’ (100 ml of colloid or crystalloid fluid over 1 minute) has been shown to 
predict fluid responsiveness in patients with circulatory failure receiving low tidal 
volume ventilation and may be a safer, yet rational approach in patients with suspected 
RVD as a small rise in cardiac filling pressures may lead to a greater increase in stroke 
volume during administration of a ‘mini-fluid bolus’ (steep portion of the Frank-Starling 
curve). 68, 69  
 
 
When found, the treatment of elevated filling pressures could be instituted in an attempt 
to restore RV geometry, reduce RV dilation and ventricular interdependence.  The use of 
diuretics is the simplest approach but hemofiltration and renal replacement therapy 
(CRRT) may be required if renal function is inadequate. However, there is no empirical 
evidence to support routine use of diuretics or CRRT in ARDS patients with RVF and 
this recommendation is based on clinical experience only. In addition, over-diuresis or 
excessive fluid removal on CRRT may rapidly lead to ‘under-filling’ of the RV (which is 
pre-load dependent) and decrease in stroke volume.  
 
2. Increasing RV contractility 
Ensuring the RV has an appropriate heart rate and rhythm can be amongst the simplest 
methods of improving RV contractility.  Right atrial contraction contributes up to 40% of 
RV filling and is of more importance when the RV compliance is poor.70, 71 Maintaining 
sinus rhythm avoids atrio-ventricular dyssynchrony and ensures the contribution of atrial 
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kick to RV filling.  Patients with atrial fibrillation should be considered for restoration of 
sinus rhythm by pharmacological means or cardioversion.  Likewise if heart block is 
present, placement of a temporary atrial pacemaker could be considered.  
Tachyarrythmias can also lead to a reduction in filling time and thus heart rate should be 
optimized to diastolic filling. 
 
Initiation of vasoactive support can be important not only in improving RV contractility 
but also in preventing hemodynamic instability.  Hypotension can lead to RV ischemia 
and subsequent further impairment of RV function that can quickly spiral into a vicious 
cycle.  Targeted systemic pressure should be higher than the pulmonary pressure.   
 
Maintenance of an appropriate systemic pressure while not excessively increasing or 
even decreasing the pulmonary artery pressures (PAPs) are the traits of an ideal 
vasopressor.  Norepinephrine has been shown in both animal models and in man to 
increase SVR while reducing PAPs.71, 72 Norepinephrine at high doses was shown to 
increase PVR over SVR preferentially and thus at high doses should be used cautiously.  
Phenylephrine has been shown to not be as effective as norepinephrine, and in certain 
situations to actually worsen RV function29.  Vasopressin is also another vasopressor that 
preferentially increases SVR over PVR and thus can be useful to maintain systemic 
pressure without worsening RV afterload. At low doses (<0.03 U/min), Vasopressin 
causes pulmonary vasodilatation, but at higher doses it increases PVR and causes 
coronary vasoconstriction and should therefore be used with caution.73, 74    
 
Dobutamine and milrinone are inodilators that provide inotropism and vasodilation of the 
systemic and pulmonary vasculature.75, 76 Due to the profound systemic vasodilating 
capabilities of these agents, systemic hypotension can result and thus they are often need 
to be paired with a vasoconstrictor.  Vasopressin, in contrast to norepinephrine, has been 
shown to be more beneficial at reducing PAPs.77 When comparing dobutamine and 
milrinone, although there are equivalent reductions in PVR and improvements in cardiac 
output between the agents, there appears to be a greater reduction in SVR and PCWP 
when using milrinone. 78 Levosimendan, a calcium sensitizing agent with inotropic and 
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vasodilatory properties has been shown to improve RV performance in ARDS patients 
with septic shock.79 As an inodilator, it could potentially improve RV-pulmonary vascular 
coupling but it does not have a proven mortality benefit in the treatment of ARDS 
patients with RVF.79 Levosimendan is approved for use in Europe but does not have 
Food and Drug Administration approval in the United States. The aforementioned 
inotropic agents should be used with caution as they can cause tachyarrhythmias and 
hypotension.  
 
 
3. Reducing RV Afterload 
Reducing RV afterload in ARDS patients with RVD can be achieved through the use of 
pulmonary vasodilators, reversal and control of precipitating factors (hypoxemia, 
hypercapnia, acidemia, hypothermia) and ‘RV-protective’ mechanical ventilation 
strategies. 28 
 
Pulmonary Vasodilators 
 
It is strongly recommended that inhaled rather than systemic pulmonary vasodilators are 
used when systemic hypotension is anticipated.28 Inhaled NO (iNO) increases intra-
cellular cyclic guanosine monophosphate and has been shown to transiently improve 
PaO2/FiO2 ratio and CO in ARDS patients with RVD.80, 81 It is recommended that iNO is 
used as a short term therapy to improve oxygenation indices  in ARDS as it does not 
improve mortality regardless of ARDS severity and has also been associated with acute 
kidney injury.28, 82, 83 Inhaled prostanoids such as prostaglandin-I2  (prostacyclin, PGI2) 
and its analogues such as iloprost, reduce PVR and improve RV performance . Use of 
nebulized iloprost in ARDS patients with pulmonary hypertension has been associated 
with an improvement in gas exchange without causing hemodynamic instability.28, 84 Oral 
sildenafil, a PDE-5 inhibitor has been shown to decrease RV systolic overload and 
enhances RV performance in ARDS patients with RVD. 85 
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The use of pulmonary vasodilators should be individualized as they can worsen 
oxygenation and shunt fraction. 86 Pulmonary vasodilatation early in the course of ARDS, 
in patients at risk of RVD (eg RVD risk score >2), and its impact on clinical outcomes 
has not been studied. 
 
‘RV-protective’ ventilation strategies 
 
Understanding lung-heart clinical crosstalk in ARDS is likely to be of paramount 
importance, as RVD does occur in patients subjected to lung protective ventilation. The 
main proposed components of RV-protective ventilation strategy include: 1) minimizing 
lung stress by limiting plateau and driving pressures; 2) prevention or reversal of 
pulmonary vasoconstriction by improving oxygenation and strict CO2 control; and 3) 
prone position to unload the RV.44, 87 
 
It has been shown that ‘low-stress’ ventilation with plateau pressure less than 26-28 
cmH2O is associated with lower incidence of RVD. 48 Driving pressure (plateau pressure-
total PEEP) has also been associated with mortality and development of RVD in 
ARDS.20, 49, 87 It is recommended that plateau pressure is kept < 27cmH2O and driving 
pressure < 18 cmH2O. 44 High PEEP recruits collapsed alveoli but can cause 
overdistension of functional lung areas. Both atelectasis and overdistension result in 
increased PVR and high RV afterload. The optimal ‘RV-protective’ PEEP levels (balance 
between alveolar recruitment and overdistension) and titration of PEEP remain 
controversial and the effect of ‘low-lung stress’ ventilation approach on the RV needs to 
be validated in large RCTs. 
 
Prone ventilation in ARDS can facilitate reduction in RV afterload by recruiting 
collapsed alveoli without causing overdistension 88 and reducing airway pressure, PaCO2, 
RV enlargement and septal dyskinesia.89 A multi-center RCT (PROSEVA) showed a 
mortality benefit in patients with severe ARDS who were ventilated in the prone 
position.4 In addition, the prone group had a lower incidence of cardiac arrest (6.8 vs 
13.5%, p<0.05) and shock (14.8 vs 21%) that may suggest a positive impact of proning 
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on hemodynamics.44 PaO2:FiO2 < 150mmHg is an accepted indication for proning 4 but 
timing and optimal duration of prone ventilation in patients with ARDS and RVD has not 
been established. Whether prone position at the onset of mechanical ventilation in severe 
‘Berlin’ ARDS prevents RVD remains unknown. A strategy whereby ARDS patients are 
ventilated in prone position based on their hemodynamic status (presence of RVD) and 
not PaO2:FiO2 ratio has not been investigated either. 
 
 
4. Extracorporeal Life Support (ECLS) 
 
Veno-venous ECMO (VVECMO) may be used in cases of severe hypoxemia (PaO2:FiO2 
< 150mmHg, on FiO2 ≥0.6 and PEEP ≥5 cmH2O) despite optimization of mechanical 
ventilation settings (higher PEEP and mean airway pressure, lung recruitment 
maneuvers), neuromuscular blockade and inhaled pulmonary vasodilators. 4, 90 VVECMO 
in ARDS has been shown to effectively unload the RV by correcting hypoxemia and/or 
hypercapnia and facilitating a least damaging (‘low-pressure’) ventilatory approach.90 
 
Veno-arterial ECMO (VAECMO) is an option for mechanical circulatory support in 
ARDS patients with RVF and cardiogenic shock refractory to vasoactive drugs. 
VAECMO (percutaneous or intrathoracic) provides respiratory and cardiovascular 
support as deoxygenated blood bypasses both the failing RV and the lungs enhancing 
unloading of the RV.91 
 
Normocapnia in ARDS can be challenging to achieve with conventional mechanical 
ventilation. An increase in mechanically triggered mandatory breaths can cause increased 
auto-PEEP, worsening hypercapnia and RVD.44 Extracorporeal CO2 removal (ECCO2R) 
devices can be used as adjuncts to invasive mechanical ventilation and could potentially 
help preserve or restore optimal RV-arterial coupling and prevent RV failure in ARDS 
patients.92 Experimental evidence suggests that ECCO2R facilitates protective ventilation, 
reduces minute ventilation by 50% and improves RV function.93 
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Although ECLS can theoretically reverse physiological causes of RVD 
(hypoxemia/hypercapnia) and facilitate ‘RV-protective’ ventilation its effect on RVD and 
ARDS mortality has yet to be proven in rigorous controlled trials.  
 
 
CONCLUSIONS 
 
Right ventricular dysfunction and failure is associated with adverse outcomes in patients 
with ARDS. Understanding of RVD pathophysiology and altered cardiopulmonary 
interactions in ARDS is crucial for the bedside management of these patients.  Future 
research should focus on validation of clinical risk scoring systems to select patients at 
risk of RVD, immediate assessment by echocardiography and early implementation of 
therapeutic measures such as early pulmonary vasodilatation and prone positioning that 
may improve prognosis in ARDS. Echocardiographic markers such as TAPSE and RV 
TDI S' velocity could serve as predictors of early RVD and guide therapeutic 
interventions based on temporal changes in RV function which is another high-yield area 
of future study. Finally, the ‘RV-protective’ ventilatory strategy combined with 
extracorporeal support may be key in management of patients with established RVD and 
form part of ARDS management guidelines if validated in prospective pragmatic trials. 
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Study 
reference 
Year Type ARDS 
definition/ 
Ventilation 
strategy 
N Diagnostic 
modality: 
TTE/TEE/PAC 
Timing of 
echocardiograph
y following 
diagnosis of 
ARDS 
Definition of RVD Prevalence 
of RVD 
Outcome Non-
survivors 
(n) 
Non-
surviv
ors 
with 
RVD 
(n) 
P (<0.05 
statistically 
significant) 
 
Wadia et 
al15 
2016 Retrospecti
ve 
Berlin/LPV 14 TTE Within 2 weeks Not defined 
(authors examined 
changes in TAPSE, 
MPI, FAC pre- and 
post- ARDS) 
42.9% 30-day 
mortality 
8 (57%) - 0.002(for 
TAPSE) 
 
Shah et 
al16 
2016 Retrospecti
ve 
Berlin/LPV 38 TTE Within 2 weeks TAPSE <17mm 55% 30-day 
mortality 
18 (47%) - 0.004 
 
Dessap et 
al17 
2015 Prospective 
observation
al 
Berlin/LPV 752 TEE Within 3 days Septal dyskinesia 
with dilated RV 
(RVEDA/LVEDA 
>0.6) 
22% Hospital 
mortality 
322 
(43%) 
78/164 
(48%) 
 
[31/54 
(57%)
] in 
severe 
RVD] 
0.17 
 
 
0.03 
 
Lazzeri et 
al18 
2015 Prospective 
observation
al 
Berlin/ LPV 21 TEE/TTE Prior to 
VVECMO 
implantation 
sPAP 
>40 mmHg or 
dilated RV 
or 
Septal dyskinesia 
with dilated RV 
(RVEDA/LVEDA 
>0.6) 
or 
TAPSE<16mmHg 
 
90.5% 
 
 
 
9.5% 
 
 
47.6% 
 
 
 
 
ICU 
mortality 
12 
(57.1%) 
- 0.004 
 
 
 
 
 
 
 
 
0.04 
 
Lhe´ritier 
et al19 
2013 Prospective 
observation
al 
American & 
European 
consensus/LPV 
201 TEE/TTE Within 48 hours Septal dyskinesia 
with dilated RV 
(RVEDA/LVEDA 
>0.6) 
22.5% 28-day 
mortality 
 
46 (23%) 11/45(
24%) 
0.79 
 
Boissier 
et al20 
2012 Prospective 
observation
al 
Berlin/LPV 226 TEE Within 3 days Septal dyskinesia 
with dilated RV 
(RVEDA/LVEDA 
>0.6) 
22% 28-day 
mortality 
 
ICU 
mortality 
114 
(50%) 
28/49 
(57%) 
 
31/49 
(63%) 
<0.01 
 
 
0.04 
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Hospital 
mortality 
 
 
33/49 
(67%) 
 
 
 0.02 
Guervilly 
et al21 
2012 Prospective 
randomize
d 
American & 
European 
consensus/ CMV 
vs HFOV 
16 
(CMV 
vs 
HFOV) 
TEE Within 48 hours RVEDA/LVEDA 
>0.6 ( RV 
Dysfunction) 
 
RVEDA/LVEDA 
>0.9 (RV Failure) 
56% 
(during 
CMV) 
 
25% 
(during 
HFOV) 
ICU 
mortality 
9 (56%) - <0.01 
 
Bull et 
al22 
2010 Retrospecti
ve 
observation
al 
American & 
European 
consensus/LPV 
475 PAC  TPG > 24 mm Hg 
(assessed 
pulmonary vascular 
dysfunction) 
- 60-day 
mortality 
49% 41 0.0006 
 
Osman et 
al23 
2009 Prospective 
observation
al 
American & 
European 
consensus/LPV 
145 PAC After 24 hours (1) 
mPAOP>25mmHg 
and (2) 
CVP>PAOP and 
(3) SVI<30ml m-2 
9.6% 28-day 
mortality 
 
90-day 
mortality 
98 (68%) 9/14 
(64%) 
0.75 
 
 
 
0.56 
 
Vieillard-
Baron et 
al24 
2001 Prospective American & 
European 
consensus/LPV 
75 TEE After 2 days of 
respiratory 
support 
RVEDA/LVEDA 
>0.6 + Septal 
dyskinesia (ACP) 
 
RVEDA/LVEDA 
>1 (Severe ACP) 
25% 28-day 
mortality 
24 (32%) - <0.2 
 
 
 
Table 1. Characteristics of studies evaluating the prognostic value of right ventricular dysfunction assessed by echocardiography for mortality in 
patients with acute respiratory distress syndrome. 
 
 
ACP = acute cor pulmonale; ARDS = acute respiratory distress syndrome; CMV = conventional mechanical ventilation; CVP = 
central venous pressure;   FAC = fractional area change; HFOV = high frequency oscillatory ventilation; ICU = intensive care unit; 
LVEDA = left ventricular end-diastolic area;  LPV = lung protective ventilation; mPAOP =  mean pulmonary artery occlusion 
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pressure; MPI = myocardial performance index; PAC = pulmonary artery catheter; PAOP = pulmonary artery occlusion pressure;  RV 
= right ventricle; RVD = right ventricular dysfunction; RVEDA = right ventricular end-diastolic area; SVI = stroke volume index; 
TAPSE = tricuspid annular plane systolic excursion; TEE = transesophageal echocardiography; TPG = transpulmonary gradient; TTE 
= transthoracic echocardiography; VVECMO = veno-venous extracorporeal membrane oxygenation 
  
 
 
 
 
 
 
